JP2014524902A5 - - Google Patents

Download PDF

Info

Publication number
JP2014524902A5
JP2014524902A5 JP2014515968A JP2014515968A JP2014524902A5 JP 2014524902 A5 JP2014524902 A5 JP 2014524902A5 JP 2014515968 A JP2014515968 A JP 2014515968A JP 2014515968 A JP2014515968 A JP 2014515968A JP 2014524902 A5 JP2014524902 A5 JP 2014524902A5
Authority
JP
Japan
Prior art keywords
seq
antigen
binding fragment
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014515968A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524902A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/042315 external-priority patent/WO2012174160A1/en
Publication of JP2014524902A publication Critical patent/JP2014524902A/ja
Publication of JP2014524902A5 publication Critical patent/JP2014524902A5/ja
Pending legal-status Critical Current

Links

JP2014515968A 2011-06-14 2012-06-13 Ｔｅｍ８抗体、そのコンジュゲートおよびそれらの使用 Pending JP2014524902A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161496737P 2011-06-14 2011-06-14
US201161496986P 2011-06-14 2011-06-14
US61/496,986 2011-06-14
US61/496,737 2011-06-14
PCT/US2012/042315 WO2012174160A1 (en) 2011-06-14 2012-06-13 Tem8 antibodies, conjugates thereof, and their use

Publications (2)

Publication Number Publication Date
JP2014524902A JP2014524902A (ja) 2014-09-25
JP2014524902A5 true JP2014524902A5 (enExample) 2015-07-09

Family

ID=47357454

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014515968A Pending JP2014524902A (ja) 2011-06-14 2012-06-13 Ｔｅｍ８抗体、そのコンジュゲートおよびそれらの使用

Country Status (5)

Country Link
US (1) US9181340B2 (enExample)
EP (1) EP2721071A4 (enExample)
JP (1) JP2014524902A (enExample)
CA (1) CA2837892A1 (enExample)
WO (1) WO2012174160A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
HK1219980A1 (zh) * 2013-03-09 2017-04-21 Baylor College Of Medicine 靶向血管的t细胞疗法
WO2014201202A1 (en) 2013-06-14 2014-12-18 Texas Tech University System Rna interference-based therapeutic against anthrax
ES2764833T3 (es) 2013-10-11 2020-06-04 The United States Of America Represented By The Sec Dep Of Health And Human Services Anticuerpos contra TEM8 y su uso
JP6795877B2 (ja) * 2013-12-25 2020-12-02 東京応化工業株式会社 表面被覆膜の形成方法及び表面被覆膜を有する太陽電池
US10758613B2 (en) * 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Intstitutes Of Health Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
WO2015191596A1 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
US10758614B2 (en) * 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
US11034757B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US11033621B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells
US11033620B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
US10799584B2 (en) 2014-06-09 2020-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
WO2015191610A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
KR20180105243A (ko) * 2016-02-09 2018-09-27 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 일본 삼나무 꽃가루 에피토프를 캡슐화하는 ｔｉｍｐｓ
JP7350313B2 (ja) 2016-12-16 2023-09-26 ブルーフィン バイオメディシン， インコーポレイテッド 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
CN108707199A (zh) * 2018-05-29 2018-10-26 廊坊康宝汇泰生物技术有限公司 靶向tem8的嵌合抗原受体t细胞及其应用
CN121419992A (zh) * 2023-05-31 2026-01-27 应世生物科技(南京)有限公司 一种靶向tem8的抗体或其抗原结合片段及其应用
WO2025179281A1 (en) * 2024-02-23 2025-08-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of cardiovascular disease with antxr1 antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2810195B1 (fr) 2000-06-16 2002-08-30 Kuhn Audureau Sa Machine de coupe pouvant etre accrochee a un tracteur et comprenant un mecanisme de coupe a rotor et couteaux perfectionne
EP1307557A2 (en) 2000-08-02 2003-05-07 The Johns Hopkins University Endothelial cell expression patterns
WO2002046228A2 (en) 2000-12-05 2002-06-13 Wisconsin Alumni Research Foundation Receptor for b. anthracis toxin
EP1572867B1 (en) 2001-04-11 2014-07-23 The Johns Hopkins University Endothelial cell expression patterns
WO2004013313A2 (en) 2002-03-28 2004-02-12 University Of Florida Antisense nucleic acids
KR20060003860A (ko) 2003-03-04 2006-01-11 기린 비루 가부시키가이샤 내피 세포 특이적 항체 및 그의 용도
WO2005038022A1 (ja) * 2003-10-20 2005-04-28 Teijin Pharma Limited 骨及び／又は関節疾患関連遺伝子
WO2005081749A2 (en) 2004-01-23 2005-09-09 Avanir Pharmaceuticals, Inc. Neutralizing human antibodies to anthraxtoxin
ITRM20060337A1 (it) 2006-06-27 2007-12-28 Biosoot Srl Gene tem8 (tumor endotelial marker 8) e sue forme di espressione ed usi diagnostici e terapeutici
CN101591395A (zh) 2009-07-13 2009-12-02 杭州屹源生物技术有限公司 抗人肿瘤血管内皮标志分子8胞外区的人源性单链抗体及其应用
US9309322B2 (en) 2010-11-12 2016-04-12 Scott & White Healthcare (Swh) Antibodies to tumor endothelial marker 8
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8

Similar Documents

Publication Publication Date Title
JP7850455B2 (ja) 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
RU2018119165A (ru) Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение
JP2016533721A5 (enExample)
JP2019532056A5 (enExample)
RU2015142815A (ru) Лечение рака с использованием антител, связывающихся с поверхностным grp78
JP2015503909A5 (enExample)
JP2020522280A5 (enExample)
JP2020522281A5 (enExample)
JP2021527640A5 (enExample)
JP2015509947A5 (enExample)
EP3504244A1 (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
JP2008546780A5 (enExample)
JP2022509156A5 (enExample)
IL259036A (en) asct2-specific binding molecules and their uses
JP2022533538A5 (enExample)
CA3118542A1 (en) Cdcp1-targeted therapies
JP2017521054A5 (enExample)
AU2019240073A1 (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
AU2017252574A1 (en) ALK7 binding proteins and uses thereof
JP2020505075A5 (enExample)
JP2024500512A5 (enExample)
JP2025506248A5 (enExample)
CN112805297B (zh) 抗人类pd-l1抗体及其用途
CN112969715A (zh) 一种抗cd47抗原结合蛋白及其应用
JP2024502670A5 (enExample)